0001193125-12-133140.txt : 20120327 0001193125-12-133140.hdr.sgml : 20120327 20120327060759 ACCESSION NUMBER: 0001193125-12-133140 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120327 ITEM INFORMATION: Other Events FILED AS OF DATE: 20120327 DATE AS OF CHANGE: 20120327 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TARGACEPT INC CENTRAL INDEX KEY: 0001124105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51173 FILM NUMBER: 12715699 BUSINESS ADDRESS: STREET 1: 200 EAST FIRST STREET STREET 2: SUITE 300 CITY: WINSTON-SALEM STATE: NC ZIP: 27101 BUSINESS PHONE: 3364802100 MAIL ADDRESS: STREET 1: 200 EAST FIRST STREET STREET 2: SUITE 300 CITY: WINSTON-SALEM STATE: NC ZIP: 27101 8-K 1 d323826d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 27, 2012

 

 

TARGACEPT, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-51173   56-2020050

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

200 East First Street, Suite 300

Winston-Salem, North Carolina

   27101
(Address of principal executive offices)   (Zip Code)

(336) 480–2100

Registrant’s telephone number, including area code

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01 Other Events.

Targacept, Inc. and AstraZeneca have determined to discontinue the Phase 2b clinical trial of TC-5214 as a “switch” monotherapy for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment, known as the EXPLORER study. Notification of the study discontinuation to applicable regulatory authorities and institutional review boards is in process. Earlier in March 2012, Targacept and AstraZeneca announced that the two companies would not pursue a regulatory filing for TC-5214 as an adjunct to antidepressant treatment for patients with MDD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TARGACEPT, INC.
Date: March 27, 2012  

/s/ Peter A. Zorn

  Peter A. Zorn
  Senior Vice President, Legal Affairs, General Counsel and Secretary